| Study number | Tumour type | Status | Phase | Details | Contact | Info |
|---|---|---|---|---|---|---|
| 1.2021 | Any Anthracycline sensitive cancer which has an injectable tumour | Open and recruiting | 1 | Open-Label Study of SQ3370 in Patients with Advanced Solid Tumours | admin@cancerresearchsa.com.au Ph: 08 8359 2565 Fax: 08 7123 6170 | Study Info |
| 2.2021 | Early stage breast cancer - for hormone blockade | Open and recruiting | 3 | Randomized, open-label, study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patient with Estrogen receptor positive, HER2 negative Early Breast Cancer - LiDERA GO42784 | admin@cancerresearchsa.com.au Ph: 08 8359 2565 Fax: 08 7123 6170 | |
| 3.2021 | Metastatic prostate cancer - which is hormone responsive | Open and recruiting | 3 | Randomised, placebo controlled, double blind study of Darolutamide plus androgen deprivation therapy (ADT) VS ADT in subject with metastatic hormone sensitive prostate cancer (mHSPC) - ARANOTE | admin@cancerresearchsa.com.au Ph: 08 8359 2565 Fax: 08 7123 6170 |
0411 454 668 enquiries@i-o-s.net
Comments are closed.